Physician profile
Amanda Mims
NPI 1821712415
$191.72
in general payments reported to CMS, 2019-2025
7 companies · $89.53 in 2025
The $89.53 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $102 · 2025: $89.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atland Pharmaceuticals, LLC | $61.19 | 2024-2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.67 | 2025 | Relistor |
| Averitas Pharma INC. | $19.97 | 2025 | Qutenza |
| Virtus Pharmaceuticals LLC | $18.76 | 2024 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $17.31 | 2024 | Movantik |
| Lantheus Medical Imaging, INC. | $15.25 | 2025 | |
| Amgen INC. | $14.57 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.